HER2+ Breast Cancer

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.

The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.

T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Sara Nunnery, MD, MSCI, and Kelly E. McCann, MD, PhD, discuss practice-changing data with T-DXd for HER2-positive breast cancer.

T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,

Catch up on insights into the global development of breast cancer treatments in the global spotlight.

Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.

The European Union has approved trastuzumab deruxtecan for patients with previously treated, HER2-positive metastatic solid tumors.

Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The FDA has approved palbociclib plus trastuzumab, with/without pertuzumab, and ET as maintenance in HR+, HER2+ metastatic breast cancer.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.

Kelly Elizabeth McCann, MD, PhD, discusses the role of post-neoadjuvant T-DXd in HER2-positive breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the clinical utility of T-DXd followed by THP for HER2-positive early breast cancer.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.